Agios Pharmaceuticals, Inc. (AGIO) Rating Reiterated by SunTrust Banks, Inc.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)‘s stock had its “buy” rating restated by stock analysts at SunTrust Banks, Inc. in a report released on Wednesday. They presently have a $80.00 price target on the biopharmaceutical company’s stock. SunTrust Banks, Inc.’s price target suggests a potential upside of 13.88% from the company’s previous close.
A number of other research firms have also weighed in on AGIO. Janney Montgomery Scott lowered shares of Agios Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday, June 26th. Cann restated a “buy” rating and set a $75.00 target price on shares of Agios Pharmaceuticals in a research report on Sunday, June 11th. ValuEngine upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Royal Bank Of Canada started coverage on Agios Pharmaceuticals in a report on Thursday, September 14th. They issued an “outperform” rating and a $78.00 price target for the company. Finally, Oppenheimer Holdings, Inc. set a $75.00 price target on Agios Pharmaceuticals and gave the stock a “buy” rating in a report on Sunday, June 11th. Four analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $75.20.
Shares of Agios Pharmaceuticals (AGIO) traded up 1.39% during midday trading on Wednesday, reaching $70.25. The company had a trading volume of 1,017,271 shares. Agios Pharmaceuticals has a one year low of $39.24 and a one year high of $71.40. The company has a 50 day moving average price of $62.68 and a 200-day moving average price of $55.80. The firm’s market capitalization is $3.40 billion.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.57) by ($0.21). The business had revenue of $11.30 million during the quarter, compared to the consensus estimate of $10.68 million. Agios Pharmaceuticals had a negative net margin of 502.12% and a negative return on equity of 68.15%. The business’s revenue for the quarter was up 62.1% on a year-over-year basis. During the same period last year, the firm earned ($1.47) EPS. On average, analysts anticipate that Agios Pharmaceuticals will post ($7.07) EPS for the current fiscal year.
In related news, insider Scott Biller sold 2,146 shares of the company’s stock in a transaction that occurred on Friday, July 7th. The shares were sold at an average price of $55.00, for a total value of $118,030.00. Following the transaction, the insider now directly owns 8,410 shares in the company, valued at $462,550. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Lewis Clayton Jr. Cantley sold 3,500 shares of the company’s stock in a transaction that occurred on Wednesday, July 19th. The stock was sold at an average price of $56.14, for a total transaction of $196,490.00. Following the completion of the transaction, the director now owns 86,697 shares in the company, valued at $4,867,169.58. The disclosure for this sale can be found here. Insiders sold a total of 131,938 shares of company stock worth $8,205,572 over the last 90 days. Corporate insiders own 10.55% of the company’s stock.
A number of institutional investors have recently made changes to their positions in AGIO. Lord Abbett & CO. LLC grew its stake in Agios Pharmaceuticals by 81.5% in the 2nd quarter. Lord Abbett & CO. LLC now owns 266,910 shares of the biopharmaceutical company’s stock worth $13,733,000 after buying an additional 119,836 shares in the last quarter. Public Employees Retirement System of Ohio increased its holdings in shares of Agios Pharmaceuticals by 52.8% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 18,353 shares of the biopharmaceutical company’s stock worth $944,000 after buying an additional 6,338 shares during the last quarter. California State Teachers Retirement System increased its holdings in shares of Agios Pharmaceuticals by 20.7% in the 2nd quarter. California State Teachers Retirement System now owns 74,157 shares of the biopharmaceutical company’s stock worth $3,816,000 after buying an additional 12,716 shares during the last quarter. Cubist Systematic Strategies LLC raised its position in shares of Agios Pharmaceuticals by 1,041.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock valued at $176,000 after buying an additional 3,123 shares in the last quarter. Finally, State Street Corp raised its position in shares of Agios Pharmaceuticals by 8.1% during the 2nd quarter. State Street Corp now owns 1,302,966 shares of the biopharmaceutical company’s stock valued at $67,036,000 after buying an additional 97,220 shares in the last quarter. Institutional investors and hedge funds own 94.40% of the company’s stock.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.